Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital (TOXO)

December 9, 2025 updated by: University Hospital, Strasbourg, France

Retrospective Descriptive Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital From 2010 to 2023

Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for recent recommendations in the context of hematopoietic stem cell transplantation. A description of this population is necessary to estimate the number of patients affected and to define their specific management (diagnosis, treatment, prevention).

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Service d'immunologie clinique - Hôpitaux Universitaires de Strasbourg
        • Contact:
        • Principal Investigator:
          • Mathilde mathilde.herber@chru-strasbourg.fr, MD
        • Principal Investigator:
          • Anne STAB, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Adult subject (≥18 years) with a positive toxoplasmosis PCR test (regardless of tissue)

Description

Inclusion Criteria:

  • Adult (≥18 years)
  • Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary).
  • At least one positive toxoplasmosis PCR test (regardless of tissue)

Exclusion Criteria:

  • Subject who has expressed opposition to the reuse of their data for scientific research.
  • HIV positive
  • Congenital toxoplasmosis
  • Isolated ocular toxoplasmosis in immunocompetent individuals

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Overall patient survival rates
Time Frame: Up to 1 year
Up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 2, 2025

Primary Completion (Estimated)

February 1, 2026

Study Completion (Estimated)

February 25, 2026

Study Registration Dates

First Submitted

December 9, 2025

First Submitted That Met QC Criteria

December 9, 2025

First Posted (Actual)

December 23, 2025

Study Record Updates

Last Update Posted (Actual)

December 23, 2025

Last Update Submitted That Met QC Criteria

December 9, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9375

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Toxoplasmosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe